Significant Improvements Observed With Apremilast in Mild to Moderate Plaque Psoriasis – Monthly Prescribing Reference

Amgen announced positive topline results from the phase 3 study of apremilast (Otezla), a phosphodiesterase 4 (PDE4) inhibitor, for the treatment of adults with mild to moderate plaque psoriasis.

The multicenter, placebo-controlled, double-blind ADVANCE study evaluated the efficacy and safety of apremilast in 595 adult patients with mild to moderate plaque psoriasis. Patients were randomized to receive either apremilast 30mg orally twice daily or placebo for the first 16 weeks followed by all patients receiving apremilast in an open-label extension phase through week 32. The primary end point was the proportion of patients with static Physicians Global Assessment (sPGA) response of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at week 16.

Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo. In addition, the study met key secondary end points including at least 75% improvement from baseline in the percent of affected body surface area (BSA); change in BSA total score from baseline; and change in Psoriasis Area and Severity Index (PASI) total score from baseline.

The safety profile of apremilast was consistent with that seen in previous trials. The most commonly reported adverse events (5%) in either treatment group were diarrhea, headache, nausea, nasopharyngitis and upper respiratory tract infection.

Detailed results will be submitted for presentation at an upcoming medical meeting.

Many patients with mild to moderate plaque psoriasis who use topical therapies still have challenges managing their psoriasis, said David M. Reese, MD, executive vice president of Research and Development at Amgen. We look forward to discussions with the FDA about the potential to bring Otezla, which has already been prescribed to hundreds of thousands of patients with moderate to severe psoriasis, to more patients who may need additional therapeutic options.

Otezla is currently approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, and for oral ulcers associated with Behets disease. It is available in 10mg, 20mg, and 30mg tablets.

For more information visit amgen.com.

View post:

Significant Improvements Observed With Apremilast in Mild to Moderate Plaque Psoriasis - Monthly Prescribing Reference

COVID-19 Outbreak Briefly Derails Phototherapy Treatment Market; Sales to Pick up Pace Once the Pandemic Begins to Recede – Cole of Duty

The global economic downtick has become worrisome for most companies in the Phototherapy Treatment market. Hence, companies are vying opportunities to gain competitive edge over other market players to capitalize on value-grab opportunities. Gain full access on our recently published report on the Phototherapy Treatment market that highlights how companies are adopting alternative business strategies to stay afloat during debilitating times.

Assessment of the Global Phototherapy Treatment Market

Market Research Reports Search Engine (MRRSE) recently published a report which provides a deep understanding of the various factors that are likely to influence the prospects of the Phototherapy Treatment market in the forecast period (20XX-20XX). The study takes into account the historical and current market trends to predict the course of the Phototherapy Treatment market in the upcoming years. Further, the growth opportunities, drivers, and major challenges faced by market players in the Phototherapy Treatment market are discussed in detail.

Request Sample Report @https://www.mrrse.com/sample/10643?source=atm

Regional Outlook

The team of analysts at MRRSE, track the major developments within the Phototherapy Treatment sphere in various geographies. The market share, size, and value of each region are discussed in the report along with explanatory graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments of leading companies operating in the Phototherapy Treatment market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers valuable insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Family physicians are playing a crucial role in diagnosing psoriasis in Canada

In Canada, the majority of the psoriasis patients are mainly diagnosed by family physicians rather than by dermatologists. The reason behind this is the lack of dermatologists and related services in Canada. For instance, according to a report published by the Economist Intelligence Unit, Canada had less than 2 dermatologists per 100,000 individuals in 2015, which is very less when compared with European countries. It has also been observed that family physicians typically prefer topical therapies than biologics/phototherapy to treat psoriasis conditions, while dermatologists prefer phototherapy more than the other available therapies/medications. This recent trend is boosting the phototherapy segment. While in the U.S. the growing population of adult women suffering from acne and psoriasis is an important factor driving revenue growth of the phototherapy segment. The population of adult women is rising with higher rates in North America than in European countries such as Germany, Italy, France and Spain. The growth in women adult acne conditions in North America is mainly due to increase in male hormonal (androgens) levels in females.

Complementary therapies to treat psoriasis conditions and combination therapies are recent trends in Western Europe, which are creating a positive impact on the phototherapy segment in the regional market

Complementary therapies such as balneotherapy along with UV radiation is quite popular in Western European countries. Balneotherapy is the oldest treatment method available to treat the psoriasis condition. In this treatment, the patient undergoes a bath in high mineralized brine, which causes a mechanical removal of skin scales and increases the sensitivity of skin to UV radiation. Combination therapies are set to witness high potential in austerity driven markets in Europe as noted by many clinic managers. Faltering out-of-pocket expenses for a service that is considered as a desire or luxury coupled with a tricky pricing of combination treatments involving a device and a drug are factors successfully helping in generating revenue in the market. This trend is very prominent in countries such as the U.K. and Spain.

Approved by the FDA to treat acne and psoriasis, blue light therapy dominates the North America and Europe phototherapy treatment market

By phototherapy type, blue light therapy dominated the North America and Europe phototherapy treatment market for psoriasis and acne, and is expected to be the most lucrative segment over the forecast period, with a market attractiveness index of 3.3. By the end of 2027, the blue light phototherapy segment is projected to reach more than US$ 1,000 Mn, expanding at a CAGR of 6.7% over the forecast period. Revenue from the Narrowband UVB phototherapy segment in the North America and Europe phototherapy treatment market for psoriasis and acne is expected to grow 1.9x by 2027 end as compared to that in 2017. The Red Light Phototherapy and Intense Pulsed Light (IPL) Phototherapy segments represent the lowest market attractiveness index of 0.3 each.

Availability of various treatments for acne and psoriasis and declining reimbursement rates are expected to hamper the growth of the phototherapy segment

Various treatments are currently available in the market to treat acne and psoriasis conditions. For instance, to treat acne conditions various drugs are available in the market such as topical/oral antibiotics and retinoid and chemical peels, among others. Due to a lot of available treatment options, physicians prescribe different treatments according to the patients skin nature and availability of drugs. Owing to the many treatment options, very few physicians prescribe phototherapy to patients. Furthermore, availability of non-office based treatments to treat acne and psoriasis conditions has a negative impact on the growth of the phototherapy segment. Furthermore, the decline of reimbursement pay and lack of adequate phototherapy units in the market are projected to hamper revenue growth of the phototherapy segment over the forecast period.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/10643?source=atm

Critical Market Information Enclosed in the Report:

Doubts Related to the Phototherapy Treatment Market Catered to in the Report:

Buy This Report @ https://www.mrrse.com/checkout/10643?source=atm

Why Opt for Market Research Reports Search Engine (MRRSE)?

Read the original here:

COVID-19 Outbreak Briefly Derails Phototherapy Treatment Market; Sales to Pick up Pace Once the Pandemic Begins to Recede - Cole of Duty

Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection – Dermatology Advisor

There is no indication that certain patients with psoriasis or patients who have received a renal transplant are at increased risk for hospitalization or death from coronavirus disease 2019 (COVID-19), finds study data published in the Journal of the American Academy of Dermatology. This is despite a patient population who were immunocompromised as a result of medication and of older age and likely possessing metabolic and cardiovascular comorbidities.

From February 20 to April 10, 2020, researchers conducted a retrospective, observational study with the aim of determining if patients of Verona, Italy, with chronic plaque psoriasis receiving biologic or other immunosuppressive therapies as well as those who has received renal transplantation had a greater risk for hospitalization or death from COVID-19 than the general population of the city.

The investigators extracted data from hospital electronic medical records of patients with psoriasis receiving biologic or other immunosuppressive therapies and patients who had received renal transplantation. The data were then compared with the records from the general population of Verona (n=257,353) provided by the national public database.

At study conclusion, 1.2% (n=3199) of the population of Verona were COVID-19 positive; this percentage included patients who survived COVID-19 and those who did not require hospitalization. Results demonstrated that none of the 980 patients with chronic plaque psoriasis receiving biologic agents were hospitalized and none died. The researchers noted that of the 243 patients who had received renal transplantation, 1 patient was admitted to hospital for fever and pneumonia but fully recovered. Patients with psoriasis receiving biologic therapy and those who had received a renal transplant demonstrated a higher prevalence of obesity, hypertension, diabetes, and history of cardiovascular disease, the study data revealed. These patients also tended to be older and were predominantly men, compared with the general population.

The absence of molecular or serological testing for COVID-19 in the study population, the considerable difference in patient sample size and that of the general population cohort, and the small number of hospitalizations and deaths in the patient group were cited by the researchers as limitations of the study. However, because the authors had access to the complete medical record for all members of the patient group, a notable strength of the study was that if there had been a case of hospitalization or death from COVID-19, it would have been detected.

Follow @DermAdvisor

Reference

Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G . Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment [published online April 21, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.04.085

Go here to read the rest:

Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection - Dermatology Advisor

What Are The Different Types of Psoriasis? – HealthCentral.com

On this page:BasicsPlaque PsoriasisScalp PsoriasisNail PsoriasisGuttate PsoriasisInverse PsoriasisPustular PsoriasisErythrodermic PsoriasisPsoriatic Arthritis

With 125 million people in the world who have psoriasis, chances are you know someone who has the condition. But what you may not know is that there are several types of the chronic skin disease. They tend to get lumped in with the most common one: plaque psoriasis, which accounts for a whopping 80% of all cases. But there are six others that look, act, and may even be treated differently than the rest. Knowing which one you have can help you get better, faster.

Red, scaly, painful patches or bumps on your skin are the telltale signs of this inflammatory skin condition. It happens when your skin cells turn over at a way-too-fast rate (10 times faster than normal), causing a pile up of cells on the skins surface that form those angry, red patches, or plaques. Why this happens isnt so clear, but researchers believe psoriasis is caused by a mix of genetics, an overactive immune system, and triggers such as bacterial infection, skin trauma, smoking, medications, and obesity, just to name a few.

As we mentioned above, there are seven different types of psoriasis:

Theres also psoriatic arthritis, a combo of psoriasis and arthritis. Heres what you need to know about the causes and treatments for each one.

This is the type youre probably thinking of when someone mentions psoriasis. Its characterized by clearly demarcated, raised, red, scaly patches called plaques that appear most commonly on your elbows, knees, scalp, and back (but they can pop up anywhere on the body).

Because it accounts for 80% of all cases, plaque psoriasis tends to get the most press. Its the type addressed in most psoriasis drug commercials, and celebs including reality star Kim Kardashian and singer Cyndi Lauper have both been vocal about being plagued with plaques.

The cause for all cases of psoriasis stems from a combo of genetics, immune dysfunction, and triggers. People who have psoriasis are also more likely to have other inflammatory diseases such as Crohns disease, heart disease, or diabetes, suggesting some link between the underlying inflammation.

A study in Archives of Dermatology that looked at over 100,000 patients with psoriasis found those with severe psoriasis had a 46% greater chance of having diabetes than those without the skin disease.

There are several treatments that target plaques. Your physician will decide which one is right for you based on your general health, any underlying conditions, and the severity of your plaque psoriasis. Your options include:

Research suggests that biologics for psoriasis might help with those other inflammatory diseases linked to the skin condition, too. A study in Cardiovascular Research found that treating psoriasis with biologics helps reduce the plaque buildup in the arteries, which leads to heart attacks and strokes.

However, once your skin plaques disappear, youre not necessarily in the clear. Exposure to your triggers can bring on a new bout of plaque psoriasis. Only 10% of people are lucky enough to have whats called spontaneous remission, when your skin clears up forever and you never have a flare up again.

If youre scratching your head over an itchy scalp condition that wont clear up with a traditional dandruff shampoo, you may have scalp psoriasis. This type can go hand-in-hand with plaque psoriasis (see above), or even appear in those who dont have any history of the skin disorder at all.

Its often confused with dandruff, because, well, it itches and causes flakes, only these flakes are typically silvery-white and scaly. You might also have painful red scales or silver plaques on your head. In severe cases, scalp psoriasis appears as thickened, crusty patches of skin not only on the hairline, but also on the forehead, back of the neck and near the ears.

Unlike dandruff, scalp psoriasis doesnt come and go with the weather, hormonal fluctuations, or changes in hair products.The cause is the same as other types of psoriasis: an overactive immune system, genetics, and triggers such as stress and certain medications. But in this case, the plaques that show up may only show up on your scalp.

Mild cases can be nipped in the bud or improved with salicylic-, coal-tar-, or clobestasol propionate-containing (a topical steroid) shampoos. More severe cases may require systemic or biologic drugs, oral treatments, light therapy, or a combination of treatments. Unfortunately, you may lose some hair with some of these treatments, which is usually temporary.

If youve nailed it with psoriasis, then you know all too well that this type brings pitted, discolored, thickened, and even deformed fingernails and/or toenails. In severe cases, the nail plate can lift from the nail bed and you may see some gunk or even blood in between.

Of all the people who have some type of psoriasis, up to 50% will also have nail psoriasis. Like scalp psoriasis, it often comes along with plaque psoriasis, but it can also accompany other types or appear all on its own, too. Those with psoriatic arthritis will have an 80% chance of having nail psoriasis, too.

The same underlying causes as plaque psoriasis are at play here, too, revving up your skin cell production. Nails are considered part of the skin (theyre literally made up of skin cells), which is why they are also affected by the disease.

Typically, mild cases are treated with topical ointments rubbed into the nails such as:

More severe cases might require:

This type doesnt bring large plaques, but instead little red bumps smaller than a fingertip. You can wind up with hundreds of them scattered on your arms, legs, and torso.

About 10% of all psoriasis cases are the guttate type. You can have a mild case with just a few spots in one area, a moderate case that covers up to 10% of your body, or a severe breakout that leaves most, or even all, of your body covered in bumps.

This type often stems from a bacterial infection such as strep throat, an upper respiratory infection, or tonsillitis. There is also a genetic component. If a family member has had guttate psoriasis, youre more likely to get it, too.

Because guttate psoriasis is commonly triggered by infections, once you treat the infection, the psoriasis usually goes away, too. If the skin condition lingers, or you have a severe case, your physician may want to treat your symptoms with topical steroids and/or phototherapy, artificial UVB light that halts the inflammatory process.

This type affects fewer than 10% of people with psoriasis. Its called inverse psoriasis because it appears in unusual places such as the groin, armpits, bellybutton, genitals, under the breasts and behind the knees. Often, its accompanied by one of the other types of psoriasis listed here.

The same underlying culprits can lead to this type, only its brought on by sweat and friction. Thats why its commonly found in areas where there is skin-to-skin rubbing and moisture. Weight seems to be a factor, too. If youre overweight, youre more likely to have skin folds, prime spots for inverse psoriasis.

The gold standard is typically topical steroids and ointments in those vulnerable spots where moisture and friction are likely. If those dont work, phototherapy, and systemic treatments are an option.

As the name implies, this type causes pus-filled bumps. These white spots can appear anywhere on your body, but most commonly the hands and feet. The bumps come on suddenly and look infected, but theyre not.

The real danger here is damage to the skins barrier, the outermost protective layer of your skin. That means your skin cant retain water or nutrients, while also allowing bacteria and other irritants to get a fast pass into your body. As a result, in some cases, pustular psoriasis can be deadly, so make an appointment with your doctor asap, if you develop it.

There are a few sub-types of pustular psoriasis:

At the risk of sounding like a broken record, genes are to blame. But researchers have dug deeper and discovered a specific gene mutation that may be responsible for pustular psoriasis.

A study in the American Journal of Human Genetics IDd the gene AP1S3. If you have this particular genetic predisposition, the triggers for pustular psoriasis are often infection, stress, hormonal changes such as pregnancy, and exposure to chemicals. Also, certain drugs such as OTC pain relievers and anti-inflammatory drugs, penicillin, and some antidepressants such as lithium can trigger a flare. Stopping a course of steroids too fast can bring on a flare of pustular psoriasis, too.

Your doctor may prescribe a topical retinol or an immune-suppressing biologic such as Remicade (infliximab) to calm inflammation and stop the bumps. In severe cases, you may get a combo of a biologic and an oral immune-calming med such as Trexall (methotrexate) to get it under control.

The rarest of all psoriasis types, erythrodermic psoriasis affects only 2% of those with psoriasis. This type causes redness from head to toe, as if your skin has been burned. Even worse, its possible that your skin could peel off in sheets.

As with the pustular type, erythrodermic psoriasis severely compromises the skins protective barrier, so swift medical attention is a must. You can also develop fever, chills, swollen, painful joints, and rapid heart rate.

This type can be triggered by a bad sunburn, an infection, drug reaction, stopping a medication too abruptly, steroid use, stress, and alcoholism.

Your doctor will likely start with an immune suppressant. To soothe your sore skin, you may be prescribed topical steroids, itch-suppressing medications, or prescription pain treatments.

An estimated 30% of people with psoriasis also have or will develop psoriatic arthritis, or PsA, a chronic autoimmune condition that affects 2-3% of the population. While psoriasis affects the skin, psoriatic arthritis affects the joints and some parts of the body where ligaments and tendons are attached to the bone, particularly in the fingers, toes, wrists, knees and spine. The result is stiffness, swelling, pain and, if not caught early, irreversible damage, which is why early diagnosis and treatment are important.

PsA is an autoimmune disease. That means your immune system gets its messages mixed up and attacks healthy tissue, in this case, of your skin and joints. Youre also more likely to develop PsA if you have a family history of it (40% of people who have it also have a family member who has it, too), you already have psoriasis, and youre between the ages of 30 and 50.

If you have this condition, youll want to see a rheumatologist, a doctor who specializes in arthritis. Treatments can range OTC non-steroidal anti-inflammatory drugs (NSAIDs) such as Advil (ibuprofen) to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, that work by slowing your immune system and your bodys inflammatory response. If those dont work, biologics may be considered.

Both can be itchy and cause shedding onto your hair, clothes and furniture. But the similarities stop there. Scalp psoriasis, like plaque psoriasis, is an autoimmune disease that is usually chronic and incurable. On the other hand, dandruff can go away on its own or be treated with a mild dandruff shampoo (if its caused by dry weather, for instance) and doesnt require medical attention.

Yes. In fact, keeping nails clean and trimmed and not biting them can help, and the cosmetic benefit can make you feel better about your nails. Be sure to tell your manicurist you have psoriasis because its easily mistaken with a fungal infection, which is contagious. One tip: Avoid long soaks. It robs your nails of moisture and that can make your nail psoriasis worse.

Around 85% of people develop skin psoriasis first or at the same time as psoriatic arthritis. Only about 15% get arthritis symptoms before the skin disease. Psoriasis is most likely to develop between 15 and 35 years old, while psoriatic arthritis shows up between ages 30 and 50.

For some people, guttate psoriasis, characterized by spotty, scaly lesions on arms, legs and torso, may come once and never return. It is commonly triggered by infections, like a common cold or strep throat. Once you treat it, it may be gone for good.

Go here to read the rest:

What Are The Different Types of Psoriasis? - HealthCentral.com

Visual Functions in Psoriatic Arthritis Sine-Psoriasis May Be Linked to Systemic Inflammation – Dermatology Advisor

Dry eye and subclinical abnormalities in visual functions in patients with psoriatic arthritis (PsA) sine-psoriasis may be related to systemic inflammation, according to study results published in the Journal of Clinical Medicine.

In this noninterventional, cross-sectional study, the disease activity of patients aged 18 to 65 years with diagnosed PsA and no evidence of skin psoriasis (n=40) was assessed by an experienced rheumatologist; a healthy control group (n=35) was also included in the study. All patients received a standard ophthalmology exam, which included best-corrected visual acuity, ocular surface disease index questionnaire, Schirmer test, and tear film breakup time (BUT). Standard automated perimetry, spectral-domain optical coherence tomography, and fundus perimetry scans were performed in all patients.

Researchers evaluated 80 and 70 eyes from patients in the PsA group (72.5% women; mean age, 5214 years) and the healthy control group (60% women; 48.713.8 years) , respectively. The best-corrected visual acuity of patients in the PsA group and the healthy control group were similar, and an abnormal ocular surface disease index (OSDI) was observed in 60% of patients with PsA. Prevalence of dry eye was significantly greater in the PsA group compared with the healthy control group (P <.0001). Approximately 75% of patients in the PsA group (n=30) were definitively diagnosed with dry eye (39.9% with BUT <10 sec; 23.4% with Schirmer 5 mm; 36.7% with both BUT <10 sec and Schirmer 5 mm).

Researchers indicated a positive correlation between OSDI and erythrocyte sedimentation rate (ESR; r=0.6; P <.001), In terms of the Schirmer test values, a negative correlation was observed between the scale of wetness and ESR (r=-0.43; P =.007). Results from standard automated perimetry indicated a higher mean deviation and pattern standard deviation in the PsA group compared with the healthy control group (P <.0001 and P =.005, respectively). In addition, ESR and C-reactive protein (CRP) showed a positive association with pattern standard deviation (r=0.3 and r=0.4; P =.04 and P =.01, respectively), while CRP was also correlated with mean deviation (r=-0.4; P =.01). Patients with PsA and the control participants demonstrated a similar visual field index (range, 98%-100%).

Assuming that relevant signs of systemic disease may be revealed as abnormalities occurring in the eye, a clinical evaluation of retinal morphology and function should be performed in order to detect subclinical damage of the visual system early, the researchers advised. In addition, careful ophthalmologic examination of patients with PsA sine-[psoriasis] may produce valuable clinical information on disease activity status. Using either [standard automated perimetry] or [fundus perimetry] and [optical coherence tomography] assessment could allow the detection of early changes in visual function even before clinically detectable retinopathy. These ancillary tests may serve as a useful monitoring tool over the entire course of the disease.

Reference

Chimenti MS, Triggianese P, Salandri G, et al. A multimodal eye assessment in psoriatic arthritis patients sine-psoriasis: evidence for a potential association with systemic inflammation. J Clin Med. 2020;9(3):E719.

This article originally appeared on Rheumatology Advisor

Read the original:

Visual Functions in Psoriatic Arthritis Sine-Psoriasis May Be Linked to Systemic Inflammation - Dermatology Advisor

Meet the Scientists on the Frontlines of Psoriasis Research – HealthCentral.com

Editor's Note: This story is part of a new series on HealthCentral called "Get Your Ph.D.!", which is geared toward people who've got the basics of their condition down and want to up their expertise. Who's ready to go pro?!

If psoriasis had a street name, it would be known as Slim Shady. Not only does the exact cause of this condition baffle even the best of scientific minds (genetics and an overactive immune system are possible culprits, as are triggers like stress, skin trauma, and weight gain), but its characteristic itchy and painful lesions can crop up anywhere from head to toe. In the world of skin conditions, psoriasis is all kinds of sly.

While there are effective treatments available to manage symptoms and stop them from getting worseincluding topicals, ultraviolet light therapy, oral meds, and biologics, which target the immune systemthere is yet to be a foolproof, one-size-fits-all cure. Whats more, larger implications about the relationship between psoriasis and other diseases are still a question mark. Now, thanks to groundbreaking studies from some seriously smart researchers, there is new hope for a better understanding and treatment of the condition. We talked with three of these doctors to find out what theyre working on. Caution: Majorly impressive science ahead.

MEET THE EXPERT:

Title: Head of the Lab of Inflammation and Cardiometabolic Diseases at the National Heart, Lung, and Blood Institute (NHLBI)

Research: Exploring the link between psoriasis inflammation and heart disease

Skin health isnt usually among the conditions a cardiologist studies, let alone treats, but for Nehal N. Mehta, M.D., psoriasis plays a starring role in his research.

It started with a single patient. I met a 45-year-old physician who had been having recurrent heart attacks with no real risk factors, and when I examined him, I saw a patch of psoriasis on his right inner thigh that hed had since med school, Dr. Mehta says.

It could have been nothing, but then again, there were no other clues to go on. Dr. Mehta started wondering. On a hunch, he and his team began examining scans of people with psoriasis, and what they found was startling: The condition was not just skin deep. When you look at these images, theres inflammation everywherein the joints, in the skin, in the liver, in the spleenthis is a whole-body disease, Dr. Mehta says.

Then they applied those findings to people who also had a heart attack. It was a eureka moment. Even if you accounted for all the other risk factors people had for cardiovascular disease, if they had psoriasis, it increased their risk for a heart attack by 53 percent, Dr. Mehta says.

As it turns out, the same overactive immune cells in the skin that lead to psoriasis can also be found in the heart arteries. In the arteries, however, the immune system is associated with plaque buildupa major risk for heart attack. So if you treat the psoriasis thats causing the immune system to be overactive, says Dr. Mehta, you can also reduce the risk of heart artery disease. Treating remote inflammation in the body can reduce the plaque that leads heart disease and heart attack, he says.

The treatment he uses is a biologic medicationa protein-based injectible drug created from living cells that targets the areas of the immune system associated with psoriasis. Using a biologic treatment redistributes fat in your body in a beneficial way, so youre not only improving the skin but also HDL, the bodys good cholesterol, as well as glucose levels which reduces the risk for diabetes.

Why are these findings so crucial? In addition to showing that patients with psoriasis may warrant early heart disease intervention, says Dr. Mehta, it also reveals a new risk factor (and treatment) for people with heart conditions. Along with diabetes, hypertension, high cholesterol, family history, and smoking, inflammation from psoriasis is an important variable in cardiac events. You have patients who are now learning about a sixth risk factor for heart attacksits pretty wild, he says.

MEET THE EXPERT:

Title: Director of the Psoriasis and Phototherapy Treatment Center and Professor of Dermatology at University of Pennsylvania Perelman School of Medicine

Research: Studying the benefits of at-home phototherapy treatment

Long used to help treat psoriasis, Ultraviolet B phototherapy improves symptoms by penetrating the top layer of the skin with narrowband UVB light, preventing skin cells from growing too quickly. Patients prefer it to systemic medications because its virtually free of side effects. But phototherapy is expensive, time consuming (it requires 12 weeks of in-office treatments), and not always covered by insurance.

Enter: Joel Gelfand, M.D., the director of the Psoriasis and Phototherapy Treatment Center and a professor of dermatology at University of Pennsylvania Perelman School of Medicine. Dr. Gelfand is studying the effects of at-home phototherapy as a lower cost, more accessible alternative to in-office treatments, so that more people can benefit from it.

Helming whats known as the LITE Study, Gelfand and his team are conducting an ongoing randomized, controlled study of 1,050 patients to compare the effectiveness of home-based phototherapy devices to office-based treatments. The study charts the success rate and safety of 12 weeks of therapy in both environments. It also documents the outcomes for three different skin toneslight skin, olive to light brown skin, and dark brown to black skinto measure tolerance and effectiveness.

Up until now, there hasnt been enough data on at-home therapies, and this has led to decisional uncertainty from patients, dermatologists, and insurers, Dr. Gelfand says. What were doing is an example of real-world pragmatic research designed to shift the practice of medicine in a way thats more patient-centered.

Not only does the study aim to provide important data on treatment response in patients of different skin colors, but it will ultimately help broaden the options for anyone struggling with this disease. Says Dr. Gelfand, Were trying to make phototherapy accessible and affordable to anyone who needs it.

MEET THE EXPERT:

Title: Assistant Professor at the University of Texas Southwestern

Research: Slowing cell metabolism to prevent hyper-skin growth linked to psoriasis

Heres the thing about psoriasis treatment: Because most medications broadly target the immune cells responsible for the disease in a system-wide way, they come with some serious side effects that are, in a word, uncomfortable. But, what if by simply targeting certain cell pathways the disease could be treated without side effects?

This is the question that lead Richard Wang, M.D., an assistant professor of dermatology at the University of Texas Southwestern, to start looking at glucose transport and metabolism to understand their roles in cell growth and division in conditions like psoriasis, which is characterized by skin overgrowth.

In a lab experiment, Dr. Wang and his team blocked glucose transport in the skin cells of mice using genetic and chemical inhibitors. Glucose is critical for cell survival and cell growth, Dr. Wang says. To maintain normal functioning throughout the body, glucose moves through transporters in very specific pathways so that growth and division of cells is controlled.

In people with psoriasis though, inflammation sends cells false signals that an infection is happening and those glucose transporters, which regulate the amount of glucose in cells, respond by letting more glucose in. All this extra glucose causes cells to divide, grow, and thickenresulting in the visible scales and inflamed skin characteristic of psoriasis. By blocking those glucose transporters in the mice, we were able to shut this process down, inhibiting the growth of skin cells and controlling inflammation without disrupting the skins normal functioning, Dr. Wang says.

While Dr. Wangs research is ongoing, the promise is clear: There is potential for a new, more targeted chemical inhibitor topical agent to treat humans with mild-to-moderate psoriasis without the side effects of traditional treatments, he says.

Read more from the original source:

Meet the Scientists on the Frontlines of Psoriasis Research - HealthCentral.com

Psoriasis and Diet: What’s the Link? – HealthCentral.com

Editor's Note: This story is part of a new series on HealthCentral called "Get Your Ph.D.!", which is geared toward people who've got the basics of their condition down and want to up their expertise. Who's ready to go pro?!

Scientists have long known that obesity and psoriasis go hand-in-hand. Like chips and salsa or gin and tonic, if you have one disease, youre likely to have the other. The reason is that a high BMI can lead to inflammation in the body, which increases the risk for developing the challenging skin condition known as psoriasisor worsening existing symptoms if you already have it. Now, a new study published in the Journal of Investigative Dermatology suggests there may be another mechanism at work: Fat cells themselves may not be the culprits, say researchers, but rather specific types of foods are to blame.

In the study, conducted at the University of California, two groups of mice were fed different diets. Once group got a typical mouse meal; the other one was given a characteristic Western diet (basically, the mouse equivalent of a moderate-to-high fat, processed-sugar diet that mimicked what humans would eat on the same meal plan). The mice kept it up for four weeks, after which scientists took stock of their skin, and found that the creatures whod been chowing on the rodent version of burgers, fries, and shakes showed visible inflammatory changes including redness, scales, and thickened skinthe same hallmark symptoms consistent with human psoriasiseven if the mice hadnt appreciably gained weight.

This is important because many people think that its obesity alone that leads to the increased risk for psoriasis, says senior study author Sam T. Hwang, M.D., Ph.D., department chair and professor of dermatology at the University of California Davis School of Medicine. What this shows is that dietary changes can have a radical impact on the skinso its not just weight that makes a difference for developing psoriasis, but the types of foods you eat.

These so-called Western foods are typically high in saturated fat (butter, red meat, cheese and other dairy products made from whole milk, for example), plant-based oils (such as palm oil, coconut oil, and canola oil) and processed ingredients, like those in many baked goods. The foods also contain high levels of simple sugars, found in fruit juices, soda, candy, and even some whole fruits like apples, bananas, and watermelon.

So, what is it about these foods, common in American diets, that causes inflammation in the first place? Researchers believe they alter the composition of the microbiome, those billions of bacteria living in your gut that help maintain general health and the health of your immune system. Changing the balance of these bacteria through diet may ultimately lead to an inflammatory response related to psoriasis.

To break it down even further (we know, its complicated), high-fat foods cause bile acids from your gall bladder and liver to go into the gut to help with digestion, says Ronald Prussick, M.D., an assistant clinical professor of dermatology at George Washington University and medical director of the Washington Dermatology Center. These acids then cause bad bacteria to form, leading to inflammation inside the body.

What this all means: The study proposes that what you eat can alter the gut microbiome, causing changes in bile acid levels, which can affect inflammation.

This theory was tested in the study when the researchers administered cholestyramine, a drug used to lower cholesterol (high levels of which are found in fast foods and other western fare), to the mice and found that it helped reduce the risk of skin inflammation. Cholestyramine was shown to bind to bile acids in the intestine and release through the stool, allowing for inflammation to be lowered in the mice, Dr. Hwang says.

Doctors have long maintained that there is no single food that can treat or cure psoriasis, and thats still true. But if you have the skin condition or are at risk for the disease (which is frequently genetically determined), limiting or eliminating foods high in saturated fats and simple sugars can lessen the chances for inflammationand therefore possibly psoriasis, Dr. Hwang says.

What to eat instead? A Mediterranean-type diet, characteristically rich in healthy fats and omega-3 fatty acids, is known to help fight inflammation. It includes foods such as olive oil, avocados, nuts, seeds, fish like salmon and lake trout, and some meat or dairy from grass-fed animals, as well as fresh vegetables and fruits low on the glycemic index, like berries. Switching to a healthier diet can increase the chances of treating psoriasis more effectively, says Dr. Prussick.

Additionally, Dr. Prussick suggests cooking on lower heat by stewing, poaching, boiling, and steaming foods rather than grilling, frying, or toasting them. Heat causes sugars in foods to bind to proteins, known as advanced glycation end products (AGEs), which causes more inflammation, he says. He also recommends cooking with acids such as vinegar or lemon juice, which can reduce AGEs by 50%.

Visit link:

Psoriasis and Diet: What's the Link? - HealthCentral.com

Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapies – Dermatology Times

The latest American Academy of Dermatology-National Psoriasis Foundation phototherapy guidelines incorporate several advances in efficacy, safety and patient convenience that were unavailable a decade ago.

RELATED:Biologic guidelines for psoriasis let providers choose

Weve come a long way in the field of phototherapy over the last 10 years, says M. Alan Menter, M.D. He is chairman of dermatology at Baylor University Medical Center, co-chair of the AAD Psoriasis Guideline Workgroup and founder of the International Psoriasis Council.

To produce the phototherapy guidelines, Dr. Menter and co-authors reviewed available data regarding previous phototherapy modalities, along with newer technologies including narrowband UVB (NB-UVB). With a wavelength of 290 to 320 nm, NB-UVB offers greater specificity and targeting for psoriasis and eczema than does broadband UVB (BB-UVB, 290 to 400 nm).

Formerly the mainstay of phototherapy, BB-UVB has been replaced by newer modalities. As monotherapy for adults with generalized plaque psoriasis, guidelines state, BB-UVB provides less efficacy than does NB-UVB, oral psoralen plus UVA (PUVA) or topical PUVA. Very few dermatologists still use oral PUVA, says Dr. Menter, although it works well for resistant psoriasis.

Now we also have intense electrodes and dye lasers, which are smaller lamps that penetrate much better for focal areas such as thick psoriasis patches on the elbows or knees, he says. Such technologies include excimer lasers (308 nm), targeted NB-UVB (311 to 313 nm) and pulsed-dye lasers (PDLs).

Whichever technology one chooses, guidelines emphasize the need to tailor dosing to the patients skin type. For example, minimal erythema dose (MED) testing with NB-UVB should begin at 250 mJ/cm2 for patients with skin types I and II, versus 350 mJ/cm2 for types III and IV.

Whereas Goeckerman therapy was a difficult, messy and time-consuming combination of light therapy and tar treatment, Dr. Menter says, physicians can supplement NB-UVB with concomitant topical therapies such as vitamin D analogs, retinoids and corticosteroids to potentially boost efficacy.

Disclosures:

Dr. Menter reports no relevant financial interests.

References:

Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81:775-804.

Visit link:

Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapies - Dermatology Times

The Dermatologist Whos Obsessed With Sun Damage – The Cut

Photo: Courtesy of the Laser & Skin Surgery Center of New York

Dermatologist Robert Anolik treats some of New Yorks most discerning faces his clients include Stephanie Seymour and Kelly Ripa but that doesnt stop him from worrying about fictional characters, too. Over the past few weeks, he, his wife, and their 7- and 5-year-old kids have been watching The Singing Detective, an 80s-era BBC show about a hospitalized mystery writer.

It has great music in it, but my kids keep asking me all these questions about the main character, whos covered in psoriasis and has psoriatic arthritis, says Anolik, a dermatologist at the Laser & Skin Surgery Center of New York. All I can think about is how that patient could be helped dramatically today with the approach of medical dermatology.

Anolik was a protege of the late Dr. Fredric Brandt, who was well-known in the beauty world for popularizing Botox. But what initially drew him to cosmetic dermatology wasnt injections or chemical peels, but DNA, RNA, and proteins. As a molecular biology major at Princeton, he spent one summer at the Institute for Genomic Research, studying the science of sequencing the human genome. In medical school, I saw how protein sequence analysis touched every field in medicine, but particularly skin and aging, he says. I approach skin with that kind of molecular framework to make it healthy and beautiful.

During his dermatological training at NYU, Anolik landed a fellowship with famed dermatologist Roy Geronemus, director of the Laser & Skin Surgery Center. Brandt was also part of the practice, and when he wanted to divide his time more evenly between his Miami and New York practices, Anolik became his official associate.

He wanted someone who also had laser expertise, which he knew I had, says Anolik. Even though we looked like total opposites, our personalities clicked.

Five years later, tragedy struck and Brandt took his own life. Anolik seamlessly took over, with high-profile clients now trusting their complexions to him.

These days, until he can see those patients again, hes been volunteering at Bellevue Medical Center, tending to patients with post-op wounds and other surgery-related issues. Stuff that needs attention by a physician, he says. Theyre all so overwhelmed, so hopefully I can help decrease the burden.

Anolik spoke with the Cut about the calming presence of Angela Lansbury, his complicated relationship with fruit, and why now is the perfect time to exfoliate.

Whats your definition of beauty? The Keats line beauty is truth; truth beauty is a chestnut for a reason. When I look at a face, my goal is to reveal its truth, that is to let its beauty become manifest, which is why I work very hard to eliminate distortions, both external (e.g., sun damage) and internal (e.g., psychological negativity).

What do you think of when you hear the term clean beauty? I get wary when I hear it. I believe in the sentiment that drives the clean beauty concept. As a scientist, however, I also believe in rigorous study over intuition and guesswork. Just because something grows on a tree doesnt mean its safe and/or effective. And even the cleanest ingredients in too high a quantity can be dangerous. For example, drinking too much water will kill us. And, conversely, an ingredient that sounds strange or worrisomely artificial can, in fact, be beneficial. A word of caution for those experimenting with only clean or alternative therapies: If you believe something is strong enough to help you, its likely strong enough to hurt you as well. So dont overdo it! And be sure to consult with a board-certified dermatologist about safe strategies.

Where, if anywhere, in your beauty (or life) routine are you not quitethat clean, green, or sustainable? I drink diet soda. Its dumb and I know better, but I do it anyway.

Please fill in the blank as it pertains to beauty or wellness: I think about ______a lot. SUN DAMAGE.

What is the opposite of beautiful? An artificial appearance. Lips that are too big or faces that are frozen are not beautiful. And believe me, I cringe more than you do when its obvious someone has had work done. Just because we can do something in cosmetic dermatology, doesnt mean we should.

What is your morning skin-care routine? Alastin Gentle Cleanser or Neutrogena Ultra Gentle Cleanser, shave, sulfacetamide wash to reduce shave irritation, LaRoche-Posay Anthelios Melt-In Sunscreen Milk SPF 60, SkinMedica HA5 Rejuvenating Hydrator.

Whats the last product you use every night? A prescription retinoid, then moisturizer. Usually Alastin Ultra-Nourishing Moisturizer or Cerave Cream.

Who cuts your hair? Garren. Asking Garren to cut my hair is like asking van Gogh to paint on a milk carton. But hes my friend; he pretends not to mind.

Toothbrush of choice: My wife bought me a Sonicare but I still use the freebie from the dentist.

Razor of choice: Gilette Fusion 5.

Shaving cream of choice: Gillette Fusion Hydra Shave Gel Ultra-Sensitive.

Hand wash of choice: Dove Foaming Hand Wash.

Hand sanitizer of choice: Purell.

Fragrance of choice: Hermes Eau dorange verte Eau de cologne.

Bath or shower: Shower, with Olay Ultra Moisture Body Wash with Shea Butter, R&Co. Television Shampoo, Television Conditioner, and Acid Wash.

What was your first grooming product obsession? In third grade, I discovered mousse. Id blow-dry my hair with it. Maybe I watched St. Elmos Fire a few too many times.

Daily carry-all of choice: Prada nylon shoulder bag. A gift from Dr. Brandt. Prada was a favorite brand of his.

What do you splurge on? My wifes very particular about our sons footwear. Lots of tiny pairs of Air Jordans, Converse, Vans, and Adidas Gazelles by our front door.

What is your classic uniform (under your lab coat)? Black or navy Brooks Brothers pants and black or navy Ralph Lauren crew neck sweater.

Whose shoes are you usually wearing? Greats Royale sneakers.

What do you own too many of? Medical journals. I know at this point that the past issues are all online where I read the new ones, but theres something enjoyable about referencing them with your handwritten notes. At some point, theyll find their way to the recycling bin.

Any secret talent or skill you possess? I can juggle.

What is your own personal definition of misery? Fruit of any kind in my desserts. I love cake but Im crushed when it turns out to be carrot, and I cannot get enough ice cream but I pout when the flavor turns out to be strawberry.

What is your own personal definition of glee? Getting my cholesterol tested. I dont eat all that well, and Im not great about exercising, but my cholesterol is always low. I find that so gratifying.

Favorite way or place to spend a weekend? Nantucket. My wifes family has a house there, and they make fun of me when I wear my aqua socks to the beach.

What do you most often disagree with others about? People who insist they need to get a base tan before a tropical vacation. This is nuts. You should avoid getting a tan before your tropical vacation and during your tropical vacation and after your tropical vacation. Heres what you should get instead: sunscreen and sun-protective clothing.

What must you adjust or fix when you see it done incorrectly? Bad Botox on someone who comes in for a first-time consultation.

Favorite CBD product: Ridgway Hemp Love Balms.

What calms you down? Seinfeld reruns on Netflix. And when Im really feeling stressed: Murder, She Wrote reruns on Amazon Prime (dont judge).

Comfort food: Oreos and milk.

Vice snack: Chili-roasted pistachios and Empire Bakery house-made Twinkies.

What do you foresee as the top beauty and wellness trends for 2020? Combination therapy, specifically more one-day treatments that combine multiple lasers and injections. We have been developing this for years and are now presenting safety data on the subject.Also, laser-assisted drug therapy, such as resurfacing lasers followed by topical applications of skin-brightener serums and platelet-rich plasma. Heres what I hope is the top beauty/wellness trend in 2020: a public repudiation of non-board-certified dermatologists performing cosmetic dermatology procedures on people.

What treatment at your practice is misunderstood and should be morepopular? Laser resurfacing. Granted, this is already a very popular treatment in our office, but I believe it should be even more popular. Somepatients come in with misinformation that laser resurfacing thins theskin. Nothing could be further from the truth. In fact, it does theopposite. It targets collagen-producing cells in the dermis andgenerates a stronger, more resilient skin.

What treatment is currently your favorite (understanding that thiscould change all the time)? Botox. And it has been for years. Precise treatment avoids artificial outcomes and allows for a refined, rejuvenated, lifted, rested appearance.

What activity do you do when the stress becomes too much these days?Cook. Ive been spending a lot of time with my cast-iron skillet. My cast-iron pizza is a favorite.

What have you been binge-watching? Ozark season three for suspense how good is Tom Pelphrey as Laura Linneys brother? And Cheers for laughs.

What has been an upside to this crazy time for you? My time with my wife and young sons, except during the screaming. And the homeschooling. And the cleaning.

Whats a good beauty treatment for someone whos stuck at home? Exfoliation. A downside of exfoliation is it can sometimes leave the skin dry and flaky, but if youre staying home, thats okay!

Conversely, what in your own grooming routine are you less on top of these days?Shaving, although my wife prefers a cleaner look, so early signs of a beard appear only now and then.

When this is all over, what are the first three to five things youll do or places youll go? The office will be my first stop! I miss my amazing patients! I expect Ill be there in overtime mode for a while getting everyone in. Id love a flat white at Laughing Man in Tribeca, maybe a burger at Odeon. Also we watched King Kong with the kids during quarantine, so my oldest wants me to take him to the top of the Empire State Building. He thinks King Kongs going to be there. I havent had the heart to set him straight.

Get the Cut newsletter delivered daily

Read the original post:

The Dermatologist Whos Obsessed With Sun Damage - The Cut

COVID-19 and psoriasis: Risks and precautions – Medical News Today

People with psoriasis may be wondering how COVID-19 might affect them. COVID-19 is a new illness resulting from infection with the novel coronavirus, or SARS-CoV-2.

At present, it is unclear how COVID-19 may affect those with psoriasis, which is an immune-mediated condition. This mean the condition occurs as a result of abnormal immune system activity. Scientists are also unsure about how it may impact the treatment of these individuals.

Some treatments for psoriasis, which are immunosuppressive medications, may increase the risk of a COVID-19, or of severe illness due to the virus. However, the effects are still unknown.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

Keep reading to learn more about the potential risks of COVID-19 for those with psoriasis, including the precautions that people can take to reduce their risk of developing COVID-19 and its complications.

The details of how COVID-19 affects those with psoriasis remain unknown, but there is not yet evidence to suggest that it affects them differently than people without the condition.

According to the National Psoriasis Foundation (NPF), if a person is not taking an immunosuppressive medication and is free from other underlying diseases, there may be minimal additional risk of them contracting SARS-CoV-2 relative to the rest of the population.

However, as the virus is highly transmissible, spreads rapidly, and replicates rapidly, everyone is at risk. Even asymptomatic people can transmit the virus to others.

The NPF note that people with severe psoriasis, such as those who are on immunosuppressive therapies or have other medical conditions, probably are at higher risk of infection.

As psoriasis is a chronic immune-mediated condition, some people may take immunosuppressant drugs to keep their symptoms under control.

These medications can reduce immune function, which may increase the risk of infection with SARS-CoV-2 or other infectious agents. Immunosuppressive drugs could also increase the risk of severe symptoms.

According to the Centers for Disease Control and Prevention (CDC), conditions or medications that weaken the immune system and cause people to become immunocompromised increase the risk of severe COVID-19.

The International Psoriasis Council (IPC) recommend that people with psoriasis who receive a COVID-19 diagnosis discuss discontinuing or postponing their use of immunosuppressant medications with their doctor.

However, the IPC caution that doctors should carefully weigh the benefit-to-risk ratio of immunosuppressive treatments on an individual basis.

The medical board of the NPF do not recommend that people with psoriasis stop their treatment unless they have an active infection. They suggest that those in high risk groups discuss their options with their doctor.

The CDC list the following as high risk:

The World Health Organization (WHO) and other expert bodies are still learning about the effects of COVID-19 on those with co-occurring conditions.

The WHO list the most common COVID-19 symptoms as:

They state that other possible symptoms include:

Some people with COVID-19 also report a loss of taste or smell.

Symptoms typically develop within 214 days of exposure to the virus. They range from mild to severe, although the majority of people experience a relatively mild form of the disease, which will not require specialist treatment in a hospital.

Some people may be asymptomatic, meaning that they have no symptoms, despite testing positive for the virus that causes COVID-19. Asymptomatic individuals can still transmit the virus to others, though.

People can reduce the risk of exposure to the novel coronavirus by:

Anyone who thinks that they may have become exposed to the virus should:

It is advisable to call ahead before presenting at an emergency facility in case they need to put safety measures in place.

The NPF recommend that people with psoriasis discuss their treatment with their doctor. A doctor may recommend continuing medications or taking a break from them.

It is important that people only adjust or stop their treatment after consulting with their doctor.

So far, there is no specific treatment or vaccine for COVID-19. In those who contract the virus and develop symptoms, treatment aims to alleviate these symptoms. Treatments include:

People who develop severe illness will require hospitalization. In the hospital, doctors may put them on oxygen or a ventilator, or provide other specialist care.

In some cases, doctors may speak to a person about participating in a clinical trial, which is very important in helping experts learn about the disease and find effective treatments.

People with psoriasis who develop COVID-19 should speak to their doctor about their psoriasis treatment while ill.

Those taking immunosuppressive medications will often need to stop treatment temporarily until their doctor says that it is safe to resume. The doctor will advise on other types of psoriasis treatment on a case-by-case basis.

When someone tests positive for the novel coronavirus, their doctor will provide them with instructions for recovery. They will also explain to the individual how to self-isolate to reduce the spread of the virus to others.

People with mild symptoms can typically recover at home, while those with severe illness often require a hospital stay.

It is difficult to determine the outlook for people with COVID-19 and psoriasis, but this generally depends on:

Data from China showed that 80% of people who develop COVID-19 have mild-to-moderate symptoms and recover well. Of the remainder, 13.8% develop severe disease, and 6.1% become critical and require intensive care.

Prompt medical treatment may improve the outlook of people with severe disease and reduce the risk of complications, which include pneumonia and organ failure. In some cases, COVID-19 can also lead to death.

At present, experts know little about the effects of COVID-19 on people with psoriasis.

However, it seems that those who are not taking an immunosuppressive medication and do not have another co-occurring disorder have a similar risk to the rest of the population.

People taking immunosuppressive therapies who receive a COVID-19 diagnosis should consult their doctor immediately. It is likely that the doctor will advise them to stop taking these medications until they recover.

There is no specific treatment for the novel coronavirus, but individuals can reduce their risk of contracting it by maintaining physical distance from others, avoiding unnecessary public outings, and practicing good hygiene.

Individuals with psoriasis should speak to their doctor about their specific case. A doctor will address any concerns that a person has, and they may adjust their treatment plan accordingly.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

View original post here:

COVID-19 and psoriasis: Risks and precautions - Medical News Today

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema – Yahoo Finance

WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of janus kinase type 1 (JAK1), in adult patients with chronic hand eczema.

Hand eczema is one of the most common skin diseases, affecting approximately 8 million Americans, and currently there are no FDA-approved therapies for this affliction, said Howard Welgus, M.D., Arcutis Chief Medical Officer. We are delighted to begin enrollment in this Phase 1/2b study of ARQ-252, our topical JAK1 inhibitor, in adult patients with chronic hand eczema. JAK inhibition has been shown to treat a range of inflammatory diseases including hand eczema, and we believe that, due to its demonstrated potency and high selectivity for JAK1 over JAK2, ARQ-252 has the potential to treat hand eczema without causing the adverse effects that may be associated with other less selective JAK inhibitors.

The Phase 1 portion of the study will assess the safety, tolerability and pharmacokinetics of once daily application of ARQ-252 cream 0.3% to both hands for two weeks in six subjects with chronic hand eczema. The Phase 2b portion of the study will assess the safety and efficacy of ARQ-252 cream 0.1% once daily and ARQ-252 cream 0.3% once daily and twice daily versus vehicle applied once daily and twice daily for 12 weeks to patients with chronic hand eczema. The Company expects to begin the Phase 2b portion of the study in the second half of 2020, and expects topline data in the second half of 2021.

About Hand EczemaHand eczema is a common, predominantly inflammatory, skin disease. It is the most common skin disease affecting the hands, with prevalence estimated at up to 2.5% of the population. Hand eczema is characterized variously by redness, fluid filled blisters or bumps, scaling, cracking, itching and pain occurring on the hands, especially the palms. It is a diverse syndrome, incorporating dyshidrotic eczema, an immune disease possibly related to atopic dermatitis; irritant contact dermatitis of the hands, which is caused by occupational irritants such as chemicals; allergic contact dermatitis of the hands, which is caused by an allergic reaction; atopic hand dermatitis, which is atopic dermatitis occurring on the hands, and hyperkeratotic hand dermatitis, which are thickened, scaly, red plaques, similar to psoriasis, on the hands. The impact of hand eczema on patients can be significant, leading to work absences or disability, social stigmatization, and psychosocial distress.

About ARQ-252 ARQ-252 is a potent and highly selective topical, small molecule inhibitor of janus kinase type 1 (JAK1). Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohns disease, and atopic dermatitis. The Company believes that due to its high selectivity for JAK1 over JAK2, ARQ-252 will be able to effectively treat inflammatory diseases without causing the hematopoietic adverse effects typically associated with JAK2 inhibition. In 2018, Arcutis exclusively licensed the active pharmaceutical ingredient in ARQ-252 for all topical dermatological uses in the United States, Europe, Japan and Canada from Jiangsu Hengrui Medicine Co., Ltd. of China. In mid-2019, Hengrui completed a Phase 2 study in rheumatoid arthritis that used the same active pharmaceutical ingredient as in ARQ-252 but dosed orally. The results confirmed that this active pharmaceutical ingredient is a highly potent inhibitor of JAK1 based on the drugs impact on rheumatoid arthritis, and was generally well tolerated at exposures well above those expected with topical administration of ARQ-252.

About Arcutis - Bioscience, applied to the skin.Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel compounds (topical roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit http://www.arcutis.com or follow the Company on LinkedIn.

Story continues

Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for ARQ-252 to treat hand eczema without causing the adverse effects associated with other JAK inhibitors; the anticipated timing of beginning the Phase 2b portion of the Phase 1/2b study; and the anticipated timing of the topline data of the Phase 2b portion of the study. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Annual Report on Form 10-K filed withU.S. Securities and Exchange Commission(SEC) onMarch 19, 2020, as well as any subsequent filings with theSEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

See the rest here:

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema - Yahoo Finance

The effects of psoriasis can be more than skin deep – PhillyVoice.com

Psoriasis is a common skin condition that causes raised, red, scaly patches of skin that can feel itchy or painful. But if that inflammation can't be kept in check, it can affect a person's entire body.

Psoriasis prompts skin cells to rapidly multiply, causing a buildup of lesions on certain skin surfaces. Many cases are mild, but severe cases can lead to permanent disfigurement and joint disease. About 30% of people with psoriasis willdeveloppsoriatic arthritis,which causes inflammation in the joints and tendons.

The condition's pathology is not really known, according to Dr. Jonathan Wolfe, head of the dermatology division at Einstein Medical Center Montgomery. But the prevailing thought is that it is an immune disorder.

New research suggests that psoriasis is a systemic disease that can affect any part of the body in which inflammation can spread, Wolfe said.

"Triggers of psoriasis include injuries, infection, stress, smoking, heavy alcohol use and certain blood pressure medicines," Wolfe said. "A family history of psoriasis is also a common theme."

Psoriasis increases risk forserious health conditionslike diabetes, obesity, high blood pressure, cardiovascular disease and autoimmune diseases.It also can lead to depression.

Psoriasis comes in various forms, including plaque psoriasis which has telltale thick, silvery scales anderythrodermicpsoriasis, in which most of the body reddens and becomes itchy and painful.

Plaque psoriasis normally develops on the elbows, knees or scalp, but it can appear on any part of the body. It tends to wax and wane at different times. Some people only will develop lesions on just a few skin surfaces while others will have the lesions across their bodies.

Erythrodermic psoriasis is the least common form, but it can result in a medical emergency especially for people with cardiac disease. This severe form of psoriasis can cause swelling from fluid retention and infection, increasing the risk of pneumonia and congestive heart failure.

It can also cause skin on most areas of the body to turn bright red and become itchy and painful. The skin sometimes falls off in sheets. People with unstable plaque psoriasis are most at-risk for developing it.

Other forms include nail psoriasis, which is identifiable by pitting in the nails or abnormal nail discoloration, and guttate psoriasis, which is similar to plaque psoriasis but results in more coin-shaped lesions. The latter form usually appears on the trunk of the body and is triggered by strep or another bacterial infection.

Inverse psoriasis, which occurs in the groin area and underneath the breasts and armpits, often is mistaken for a fungi infection. That can delay a patient from receiving the correct treatment.

Pustular psoriasis develops as white pustules of noninfectious pus that are surrounded by red skin, causing people to feel sick with fever and chills.

Additionally, some patients with psoriasis will develop lesions on areas that are notnormally affected by the condition a development known as the Koebner phenomenon.

Treatment options range from topical medications like corticosteroids, retinoids and vitamin D analogues to oral and injectable medications.

For more severe cases, narrow ultraviolet B phototherapy and photochemotherapy are used. Photochemotherapy requires patients to take light-sensitizing medicine before being exposed to UVB rays.

There also are biologic drugs made from living cells that target specific parts of the immune system, leading to better control of symptoms and better quality of life. They have changed the way psoriasis has been treated in the last 25 years, Wolfe said.

Anyone who develop psoriasis should talk to their doctor as soon as possible. Wolfe said,"If left untreated, psoriasis can make routine things uncomfortable and cause serious complications."

More here:

The effects of psoriasis can be more than skin deep - PhillyVoice.com

Rates of Anxiety, Depression with Apremilast vs Other Psoriasis Treatments – Dermatology Advisor

In patients with psoriasis, those who take apremilast have similar rates of anxiety and depression as patients prescribed other non-corticosteroid systemic psoriasis treatments, according to study results published in the Journal of the European Academy of Dermatology and Venereology.

Little is known about whether systemic treatments for psoriasis and psoriatic arthritis (PsA) are associated with an increased risk for anxiety and depression and whether these risks differ in both treatments. Therefore, the researchers sought to quantify the risk for incident-treated anxiety, depression, and mixed anxiety plus depression in patients treated with apremilast compared with patients prescribed other treatments for psoriasis and PsA.

They found that among the 31,274 patients with psoriasis (43.1% women, median age 49.3 years), patients treated with apremilast alone (n=3913, 12.5%) had a similar risk for incident-treated depression, anxiety, and anxiety plus depression compared with patients treated with conventional disease modifying antirheumatic drugs (n=56511, 20.8%) or biologic monotherapies. In 30,426 patients with PsA (43.6% women, median age 52.9 years), similar rates were noted for incident-treated depression and anxiety plus depression regardless of treatment; however, apremilast alone was associated with a slightly increased risk for treated anxiety compared with other PsA treatments even after adjustment for demographics and history of psychiatric disorders.

The investigators concluded that, Overall, the results of this study provide reassurance that apremilast used for the treatment of psoriasis or PsA is not associated with a high risk for incident treated depression, anxiety, anxiety [plus] depression. They added that, Among PsA patients, users of apremilast had similar rates of depression and anxiety [plus} depression compared to users of other systemic noncorticosteroid PsA drugs; however, the rate of anxiety was slightly higher.

Disclosure: This clinical trial was supported by Celgene Corporation (Summit, NJ 07901). Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of treated anxiety and treated depression among patients with psoriasis and PsA treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database [published online January 25, 2020]. J Eur Acad Dermatol Venereol. doi: 10.1111/jdv.16231

Follow this link:

Rates of Anxiety, Depression with Apremilast vs Other Psoriasis Treatments - Dermatology Advisor

Woman creates Afro hair care brand to help with her scalp psoriasis – Metro.co.uk

Alopecia left Tayshan too anxious to leave the house (Picture: Earth Elixir)

A woman who suffered for years with psoriasis on her scalp and significant hair loss has created her own all-natural haircare brand because the prescribed treatments for these conditions didnt work for Afro hair.

Tayshan, from Streatham, south London, had painful psoriasis on her scalp that caused hair loss and, eventually, alopecia. She also struggled with hair growth, with her hair never reaching past her shoulders.

I would go to the doctors and they would recommend another shampoo telling me to wash my hair three times a day, or suggest another steroid cream, Tayshan tells Metro.co.uk. They had no understanding of Afro hair at all and the damage that would be caused with these products.

Hair was always really important for Tayshan, and she says her experience with psoriasis and alopecia gave her such bad anxiety that she didnt even want to leave the house.

I felt so embarrassed that people could either see flakes from the psoriasis or bald patches from the alopecia, she says.

As women of colour we grow up with such emphasis put on our hair and are told that it is intricately tied to our beauty. I really suffered with that growing up, being mixed-race and not having the typical loose curls that people associate with being mixed-race I had grown up really fixating on my hair.

So, suddenly having bald patches everywhere I really felt like I had lost part of my identity.

At the time, Tayshan was also pregnant with her second child and was conscious that the products that she was putting on her scalp could be absorbed into her body and she didnt want that for her baby.

I decided enough was enough and started exploring the natural path of hair care, says Tayshan. Through a lot of research, trials, tribulations and testing I decided I was going to make my own natural products, as everything on the market includes ingredients that arent actually good for our hair or skin.

Tayshan, who has a degree in forensic science, also took inspiration from her daughter when creating her products.

I really wanted her to enjoy her curls, coils and kinks and embrace her hair, explains Tayshan. I didnt want her to spend her whole childhood not enjoying her hair and wishing it was like other peoples. I also wanted to have products that I knew I could use on her that was completely natural.

Tayshan has now been making her own products for two years, and she says the change in the quality, health and length of her hair has been unbelievable.

Not only is the growth astounding but it has never felt so healthy, shiny, strong, thick and my bald patches have completely gone! she says.

After sharing some products with family and friends I was encouraged to sell my products so everyone can try them. So I launched my brand Earth Elixir a range of homemade hair care products made using natural ingredients from the earth, primarily Ayurvedic herbs, which I created three weeks after my third child was born.

Tayshans products are natural, organic and entirely vegan, they include an Ayurvedic hair oil, a shea, mango and chebe whip, and a leave-in hair tea set

I also want woman to know that they can follow their dreams and nothing should stop them, says Tayshan. Many said that I wouldnt be able to do it with a seven-year-old, a 14-month-old and a newborn baby, but I have done it, customers are loving it and feedback has been amazing.

Tayshan hopes her products can give other black and mixed-race women healthier curls, kinks and coils and help to improve their confidence.

Have you created your own business or achieved something against the odds?

Get in touch: metrolifestyleteam@metro.co.uk.

MORE: How to deal with coronavirus panic when youre experiencing health anxiety

MORE: Racism and damaging stereotypes prevent east Asian women from taking part in sport

MORE: BAME millennials much more likely to be in unstable jobs than white workers

Read more here:

Woman creates Afro hair care brand to help with her scalp psoriasis - Metro.co.uk

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral…

WESTLAKE VILLAGE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will showcase data on its investigational program studying topical roflumilast cream (ARQ-151) in patients with chronic plaque psoriasis at the 2020 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO, on March 20-24, 2020.

We are delighted to participate in the scientific exchange at this years AAD meeting, said Howard Welgus, MD, Chief Medical Officer at Arcutis. Patients and dermatologists need new and better topical treatment options that provide improved efficacy, safety and tolerability for patients with plaque psoriasis. We look forward to sharing data that demonstrate how topical roflumilast cream could, if approved, provide a once daily treatment option that effectively addresses the current challenges of treating plaque psoriasis with topical therapies."

Title: ARQ-151, Roflumilast Cream, Significantly Improves Chronic Plaque Psoriasis in Phase 2b StudySession: S027 - Late-breaking Research: Clinical TrialsPresenter: Dr. Linda Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at the Henry Ford Hospital in Detroit, MichiganDate: Saturday, March 21, 9:00 9:10 a.m. MTLocation: Bellco Theatre 2

In addition, results from the Phase 1/2a study of topical roflumilast cream in chronic plaque psoriasis have been accepted for an e-poster presentation.

Title: ARQ-151, Roflumilast Cream, Improved Psoriasis in Phase 2a StudyAbstract/poster number: 15309Date: ePosters will be presented Friday, March 20 - Sunday, March 22, 9 a.m. - 5 p.m. MT

About Topical Roflumilast Cream (ARQ-151)Topical roflumilast cream (ARQ-151) is a topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation. Roflumilast was approved by the FDA for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, and has shown greater potency based on IC50 values (a non-clinical measure of a drug's potency) than other PDE4 inhibitors.

About Arcutis - Bioscience, applied to the skin.Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel compounds (topical roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit http://www.arcutis.com or follow the Company on LinkedIn.

Contact:John W. SmitherChief Financial Officerjsmither@arcutis.com

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

Read the original here:

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral...

DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs – Yahoo Finance

Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting 2019

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time

CUPERTINO, Calif., March 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2019 and provided a corporate update.

"The highlight of the year for DURECT in 2019 was achieving positive results from our DUR-928 Phase 2a alcoholic hepatitis (AH) study, which were featured in multiple presentations at the Liver Meeting 2019, including a late-breaking oral presentation by Dr. Tarek Hassanein," stated James E. Brown, D.V.M., President and CEO of DURECT. "In addition, we have already exceeded our 60 patient enrollment target in the ongoing NASH trial, and the last patient is scheduled to begin the 28-day dosing period next week. We are on track to announce top-line NASH data mid-year. We are also making steady progress toward starting a Phase 2b AH clinical trial by mid-year. In January 2020, the FDA held an Advisory Committee meeting to discuss our POSIMIR NDA resubmission. Subsequently, we have continued to interact with FDA as they continue their review."

Potential major milestones in 2020:

Update on Selected Programs and Transactions:

Epigenetic Regulator Program. DUR-928, the lead product candidate in the Company's Epigenetic Regulator Program, is an endogenous, orally bioavailable, first-in-class small molecule, which may have broad applicability in acute organ injuries such as AH, and in chronic liver diseases such as non-alcoholic steatohepatitis (NASH).

Clinical Trials

Alcoholic Hepatitis (AH)

Non-Alcoholic Steatohepatitis (NASH)

Psoriasis

POSIMIR (bupivacaine extended-release solution) Post-Operative Pain Relief Depot. POSIMIR is the Company's investigational post-operative pain relief depot that uses the Company's patented SABER technology and is designed to deliver bupivacaine to provide up to 3 days of pain relief after surgery.

Gilead Collaboration. Theinvestigational long-acting injectable HIV product using DURECT's SABER technology under development with Gilead is currently being re-formulated and will undergo additional pre-clinical development work.

Debt Amendment. In December 2019, the Company amended its existing $20 million term loan with Oxford Finance such that principal payments will commence 18 months later than previously scheduled (i.e., commencing December 1, 2021 rather than June 1, 2020) and the final maturity date has been moved back by 18 months (i.e., from November 1, 2022 to May 1, 2024). The interest rate and final payment remain unchanged, and the Company paid Oxford Finance an amendment fee of $825,000.

Earnings Conference Call

We will host a conference call today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss fourth quarter 2019 results and provide a corporate update:

A live audio webcast of the presentation will be also available by accessing DURECT's homepage at http://www.durect.com and clicking "Investors." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under "Event Calendar" in the "Investors" section.

About DURECT Corporation

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DURECT's lead candidate, DUR-928, has demonstrated the ability to regulate the expression of genes involved in lipid metabolism, inflammatory responses and cell survival. This drug candidate is currently in Phase 2 development for the treatment of alcoholic hepatitis (AH) and Phase 1 development for the treatment of nonalcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. A key product candidate in this category is POSIMIR (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. DURECT has also entered into an agreement with Gilead Sciences to develop and commercialize a long-acting injectable HIV investigational product using DURECT's SABERtechnology. For more information about DURECT, please visit http://www.durect.com.

Story continues

DURECT Forward-Looking Statement

The statements in this press release regarding clinical development and plans for DUR-928, including plans to announce top-line data from the Phase 1b NASH trial by mid-year, and initiate a Phase 2b trial of DUR-928 in AH by mid-year, potential regulatory approval of POSIMIR, potential commercial relationships for POSIMIR if approved or other license and collaboration agreements, and the potential benefits and uses of our drug candidates, including the potential use of DUR-928 to treat acute organ injuries such as AH and chronic liver diseases such as NASH , are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not replicate the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or POSIMIR, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to successfully re-formulate the investigational long-acting injectable HIV product under development with Gilead, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 5, 2019 under the heading "Risk Factors."

NOTE: POSIMIR and SABER are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

DURECT CORPORATION

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts)

(unaudited)

Three months ended

Twelve months ended

December 31

December 31

2019

2018

2019

2018

Collaborative research and development and other revenue

$ 7,249

$ 775

$ 18,129

$ 8,207

Product revenue, net

3,436

2,852

11,435

10,357

Total revenues

10,685

3,627

29,564

18,564

Operating expenses:

Cost of product revenues

1,397

1,093

4,143

4,263

Research and development

9,454

5,887

30,209

25,501

Selling, general and administrative

3,794

3,539

14,363

12,419

Total operating expenses

14,645

10,519

48,715

42,183

Loss from operations

(3,960)

(6,892)

(19,151)

(23,619)

Other income (expense):

Interest and other income

338

238

1,074

870

Interest and other expense

(609)

(645)

(2,501)

(2,573)

Net other expense

(271)

(407)

(1,427)

(1,703)

Net loss

$ (4,231)

$ (7,299)

$(20,578)

$(25,322)

Net loss per share

Read the rest here:

DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs - Yahoo Finance

How stress affects your skin and what to do about it, according to experts – The Independent

We have all experienced stress in some form or another, whetherfor a shortor long period of time. This emotional tension stems from unavoidable parts of everyday life, including work, family problems, financial woes and the digital pressures of social media.

While the anxiety that arises may originally occur in your brain, the consequences can play out physically. And no, we dont just mean tense shoulders and furrowed brows.

According to dermatologist Dr Anil Budh-Raja, daily stressors can also manifest in your skin, triggering or worsening a wide range of conditions such as acne, psoriasis, eczema and even hair thinning. Stress causes a change in brain and body chemistry and has a significant impact on our skin, Dr Budh-Raja explains, describing the process as the brain-skin connection.

Sharing the full story, not just the headlines

To understand how stress and anxiety can affect the skin, Dr Budh-Raja says we must first understand a little about the endocrine system.

The endocrine system is comprised of a number of glands that produce hormones and, when everything is in place, it allows the human body to work like a well-oiled machine. However, when outside factorssuch as stressintervene, this intricate system can slip out of sync.

During moments of tension the body produces excess cortisol, often referred to as the stress hormone, which wreaks havoc on everything from your immune system to blood pressure. Stress increases cortisol production from the adrenal glands, which in turn increases sebaceous gland activity, to produce more oil and sebum, Dr Budh-Raja explains.

The result can be acne and increased sensitivity of our skin. Cortisol also weakens the skins immune system, leading to oxidative stress which manifests itself as wrinkles, lines and lacklustre skin.

It also increases inflammation on the body and conditions like eczema, rosacea and psoriasis can flare up.

Dr Sarah Coles, a chartered clinical psychologist, agrees, adding that the onset and consequences of stress can often form a vicious cycle.

Anxiety and/or stress, which can be caused by skin conditions such as eczema, in fact can exacerbate the condition due to the bodys inflammatory responses such as producing cortisol or interrupting sleep, Coles says.

On Thursday, a series of photos titled How Do You C Me Now? were exhibited at the Oxo Tower Wharf in London to inspire the world to love the skin you are in

Brock Elbank/SWNS

The models featured in the photos, taken by London-based photographer Brock Elbank, live with a potentially life-threatening skin condition called congenital melanocytic naevus (CMN)

Brock Elbank/SWNS

According to the National Organisation of Rare Disorders (NORD), CMN are visible pigmented proliferations in the skin that are present at birth that can cover up to 80 per cent of the body. CMN are a known risk factor for melanoma - a type of cancer that develops from the pigment-containing cells

Brock Elbank/SWNS

CMN can be light brown to black patches or plaques, can present in variable ways, and cover nearly any size surface area or any part of the body, NORD states

Brock Elbank/SWNS

Small to medium CMN are predicted to occur in more than one in a 100 births while large and especially giant CMN (covering a a predicted diameter at adult age of at least 20 cm on the body) are estimated to present themselves in around 1 in 50,000 births

Brock Elbank/SWNS

The exhibition, which is being supported by UK CMN charity Caring Matters Now, has been presented throughout 30 different portraits and aims to challenge "conventional perceptions of beauty"

Brock Elbank/SWNS

A spokesperson from Caring Matters Now says: People with CMN often feel isolated due to the rarity of the condition and have to deal with negative comments because of their visible difference, resulting in low self-esteem"

Brock Elbank/SWNS

Several of the individuals photographed for the exhibition have never shown their birthmarks in public before.

Brock Elbank/SWNS

In a world where people work hard to stand out from the crowd, 'How Do You C Me Now?' aims to celebrate diversity and educate the public about this rare condition," a spokesperson from the charity added

Brock Elbank/SWNS

Admission to the exhibition is free and will run for 10 days before touring the world

Brock Elbank/SWNS

On Thursday, a series of photos titled How Do You C Me Now? were exhibited at the Oxo Tower Wharf in London to inspire the world to love the skin you are in

Brock Elbank/SWNS

The models featured in the photos, taken by London-based photographer Brock Elbank, live with a potentially life-threatening skin condition called congenital melanocytic naevus (CMN)

Brock Elbank/SWNS

According to the National Organisation of Rare Disorders (NORD), CMN are visible pigmented proliferations in the skin that are present at birth that can cover up to 80 per cent of the body. CMN are a known risk factor for melanoma - a type of cancer that develops from the pigment-containing cells

Brock Elbank/SWNS

CMN can be light brown to black patches or plaques, can present in variable ways, and cover nearly any size surface area or any part of the body, NORD states

Brock Elbank/SWNS

Small to medium CMN are predicted to occur in more than one in a 100 births while large and especially giant CMN (covering a a predicted diameter at adult age of at least 20 cm on the body) are estimated to present themselves in around 1 in 50,000 births

Brock Elbank/SWNS

The exhibition, which is being supported by UK CMN charity Caring Matters Now, has been presented throughout 30 different portraits and aims to challenge "conventional perceptions of beauty"

Brock Elbank/SWNS

A spokesperson from Caring Matters Now says: People with CMN often feel isolated due to the rarity of the condition and have to deal with negative comments because of their visible difference, resulting in low self-esteem"

Brock Elbank/SWNS

Several of the individuals photographed for the exhibition have never shown their birthmarks in public before.

Brock Elbank/SWNS

In a world where people work hard to stand out from the crowd, 'How Do You C Me Now?' aims to celebrate diversity and educate the public about this rare condition," a spokesperson from the charity added

Brock Elbank/SWNS

Admission to the exhibition is free and will run for 10 days before touring the world

Brock Elbank/SWNS

Stress can also make us less likely to engage in healthy habits, for example,we might work longer hours, eat less well, or drink more caffeine and alcohol.

When troubles are piling up, it can often feel like the worst time for pimples to populate your face, but they often do. While it can be frustrating, science says it makes perfect sense for stress to exhibit itself physically.

A 2015 study into the effects of stress as a causative or maintaining factor in psoriasis showed that about half of participants said their first experience with the disease came during a particularly difficult time in their lives, while 63 per cent said their symptoms worsened when they felt anxious or under pressure.

Similarly, a separate 2017 study of female medical students found that for 74 per cent of participants, anxiety and stress were exacerbating factors of their acne.

Thankfully, experts suggest that much of the skin damage caused by stress can be mitigated by focusing on daily moments of self-care.

When it comes to looking after your skin during periods of extreme stress, Dr Adam Friedmann, a consultant dermatologist, recommends eating a healthy balanced diet, protecting the skin from UV rays using a high factor SPF and incorporating a moisturiser that contains anti-inflammatory ingredients into your skincare routine to help improve any redness, flaking or itching.

Dr Budh-Raja agrees, advising that anyone with stressed out skin invests in products that contain soothing ingredients such as aloe vera, chamomile, oatmeal, rosemary extract and niacinamide, which restores the surface of skin against moisture loss and dehydration.

While it is good to know that we can find remedies to help counteract the effects of anxiety on the beauty counter, Dr Coles says it is also important to address the root of the problem and to try tomanage stress levels using alleviation techniques such as yoga and meditation.

There are lots of ways to manage stress in daily life, for example having a good sleep routine consisting of settling in a dark room with no bright screens an hour before bed and waking up at the same time each day, Coles says.

It is also important to have a good repertoire of coping strategies for managing stress that work for you. I like to think of this as having a menu to choose from as different strategies often help in different situations.

She continues: For some people this might be going for a long walk, spending some time outside, reading, talking with a friend, mediation, yoga, or some other form of exercise.

So if you know youre about to enter a stressful period, try to build in time for the activities that will help you to feel calm and rested your skin will thank you.

Originally posted here:

How stress affects your skin and what to do about it, according to experts - The Independent

Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson -…

Favorable safety profile is a substantial benefit in the treatment of chronic diseases that require long-term dosing

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it is submitting its annual Drug Safety Update Reports (DSUR) for both Piclidenoson and Namodenoson to the governing health regulatory agencies where its drug candidates are currently treating patients. Submission of the DSUR is an annual requirement for investigational-stage new drugs under development in territories which subscribe to the International Council for Harmonization guidelines, including the U.S. Food and Drug Administration and the European Medicines Agency. The DSUR includes updates on drug safety information such as adverse events, suspected unexpected serious adverse reactions, and other indicators of potential risk. Can-Fites reports being filed this year extend the growing body of documentation showing both Piclidenoson and Namodenoson have favorable safety profiles and risk-benefit ratios in more than 1,500 patients.

Dr. Michael Silverman, M.D., Can-Fites Medical Director, commented, "We welcome the opportunity to compile our cumulative data on a regular basis, as afforded by the DSUR process. As in years past, these snapshots of our safety data continue to confirm that both of our A3AR drugs in development are well-tolerated. We are pleased that there are no emerging safety concerns that could put patients at risk or impede our efforts to develop new drugs to meet unmet patient needs. These latest data are particularly robust, as we have achieved over 50% enrollment in both of our Phase III studies for Piclidenoson, as well as having completed two Phase II trials for Namodenoson."

Piclidenoson is currently in two Phase III studies, one for the treatment of moderate-to-severe psoriasis to establish superiority versus placebo and non-inferiority versus Otezla with over 50% of the planned 407 patients already enrolled; and another for the treatment of moderate-to-severe rheumatoid arthritis in newly diagnosed patients to establish non-inferiority to MTX, the standard of care, with over 50% of the planned 500 patients enrolled, and an interim analysis is planned. Namodenoson has completed a 78-patient Phase II study in liver cancer, and Can-Fite is currently preparing for a Phase III trial in this indication. Namodenoson has also recently completed enrollment in a 60 patient Phase II study in the treatment of NASH, with topline results expected later this month.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005502/en/

Contacts

Can-Fite BioPharmaMotti Farbsteininfo@canfite.com +972-3-9241114

Originally posted here:

Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson -...

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments & Diet

Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.

Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.

Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.

Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.

Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.

Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.

Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.

Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.

National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.

Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.

Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.

View original post here:

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments & Diet

Addition of Apremilast to Biologic Therapy Is Successful for Treating Psoriasis in Biologic Fatigue – Dermatology Advisor

The combination of apremilast with biologics is safe and associated with reductions in the mean Psoriasis Area and Severity Index (PASI) score in patients with psoriasis who have recently shown biologic fatigue, according to study results published in the Journal of Dermatology.

The study was a retrospective analysis of efficacy and safety results of a combination psoriasis treatment regimen consisting of apremilast and biologics (n=14). Patients included in the analysis were initially treated with 1 biologic, but after the efficacy of the biologic(s) declined, apremilast was added to the existing treatment program. Biologics included infliximab, adalimumab, secukinumab, ixekizumab, and ustekinumab.

Changes in the PASI score, as well as achievement of 75% and 50% reductions in PASI Score (PASI-75 and PASI-50, respectively), were assessed at weeks 0, 12, and 24 after the apremilast addition.

A total of 11 patients achieved a 90% improvement in PASI score after biologic therapy, with the lowest PASI scores ranging from 0 to 3.8 (mean, 1.30.3). Prior to biologic treatment, PASI scores in the overall cohort ranged from 5.9 to 39.0 (mean, 19.52.7). The mean PASI score before the addition of apremilast to biologic therapy was 3.20.4. The addition of apremilast to the existing biologic treatment protocol decreased the mean PASI score to 1.60.3 at 24-week follow-up. Approximately 50% of patients had achieved PASI-50, whereas only 29% achieved PASI-75 at 24 weeks.

There were 4 patients who developed diarrhea during the 24 weeks and 1 patient reported both diarrhea and nausea. In 2 patients, weight loss >5% of body weight occurred. Adverse events were not severe enough to cause any patient to discontinue the combination treatment.

Study limitations were the small number of patients, the inclusion of only patients with biologic fatigue, and its retrospective nature.

Based on their findings, the investigators concluded that apremilast could be safely combined with a biologic in psoriatic patients who are not responding adequately to a biologic alone.

Follow @DermAdvisor

Reference

Takamura S, Sugai S, Taguchi R, Teraki Y. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue [published online December 22, 2019]. J Dermatol. doi:10.1111/1346-8138.15193

Read more here:

Addition of Apremilast to Biologic Therapy Is Successful for Treating Psoriasis in Biologic Fatigue - Dermatology Advisor